Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (R/M-SCCHN): 5-year follow-up …
JB Vermorken, E Remenar, R Hitt, A Kawecki, S Rottey… - 2014 - ascopubs.org
6021^ Background: The EXTREME trial demonstrated that patients with R/M-SCCHN benefit
significantly from the addition of cetuximab to first-line platinum-based CT in relation to …
significantly from the addition of cetuximab to first-line platinum-based CT in relation to …
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients …
J Baselga, JM Trigo, J Bourhis, J Tortochaux… - Journal of clinical …, 2005 - ascopubs.org
Purpose To evaluate the efficacy and safety of the antiepidermal growth factor receptor
monoclonal antibody cetuximab in combination with platinum-based chemotherapy in …
monoclonal antibody cetuximab in combination with platinum-based chemotherapy in …
Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN …
J Guigay, J Fayette, AF Dillies, C Sire, JN Kerger… - 2012 - ascopubs.org
5505 Background: Cetuximab in combination with platinum and 5FU (PFEx) has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …
Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN …
J Guigay, J Fayette, A Dillies, C Sire… - Journal of Clinical …, 2011 - ascopubs.org
5567 Background: Cetuximab in combination with platinum and 5FU has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …
Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck
WN William Jr, ES Kim, RS Herbst - Nature Reviews Clinical Oncology, 2009 - nature.com
We discuss the results of the phase III EXTREME (Erbitux in First-Line Treatment of
Recurrent or Metastatic Head and Neck Cancer) trial. In this study, 442 untreated patients …
Recurrent or Metastatic Head and Neck Cancer) trial. In this study, 442 untreated patients …
Approval summary: cetuximab in combination with cisplatin or carboplatin and 5‐fluorouracil for the first‐line treatment of patients with recurrent locoregional or …
MH Cohen, H Chen, S Shord, C Fuchs, K He… - The …, 2013 - academic.oup.com
Abstract Learning Objectives Compare survival outcomes among patients with SCCHN
treated with a platinum/5‐FU regimen with and without cetuximab. Compare adverse event …
treated with a platinum/5‐FU regimen with and without cetuximab. Compare adverse event …
Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum …
M Knoedler, TC Gauler, V Gruenwald, A Matzdorff… - Oncology, 2013 - karger.com
Background: Cetuximab and docetaxel have single-agent activity in squamous cell
carcinoma of the head and neck (SCCHN). The efficacy of their combination was evaluated …
carcinoma of the head and neck (SCCHN). The efficacy of their combination was evaluated …
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative …
B Burtness, MA Goldwasser, W Flood… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Therapy of recurrent/metastatic squamous cell carcinoma of the head and neck
results in median progression-free survival (PFS) of 2 months. These cancers are rich in …
results in median progression-free survival (PFS) of 2 months. These cancers are rich in …
Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a …
J Trigo, R Hitt, P Koralewski, E Diaz-Rubio… - Journal of Clinical …, 2004 - ascopubs.org
5502 Background: Pts with refractory SCCHN have a poor prognosis with few therapeutic
options. Cetuximab (Erbitux), an IgG1 monoclonal antibody that binds selectively to EGFR …
options. Cetuximab (Erbitux), an IgG1 monoclonal antibody that binds selectively to EGFR …
[HTML][HTML] Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic …
M Tahara, N Kiyota, T Yokota, Y Hasegawa, K Muro… - Annals of …, 2018 - Elsevier
Background The standard of care for first-line treatment of recurrent and/or metastatic
squamous cell carcinoma of the head and neck (R/M SCCHN) is combination treatment with …
squamous cell carcinoma of the head and neck (R/M SCCHN) is combination treatment with …